Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of Type 1 Diabetes-Reply.

JAMA·2026
Same author

Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).

Diabetes care·2026
Same author

Everyone or Just Some? Cost-Effectiveness of General Population Versus Targeted Screening Strategies for Type 1 Diabetes in Canada.

Diabetes care·2026
Same author

Type 1 Diabetes: A Review.

JAMA·2026
Same author

Identification of a type 1 diabetes-associated T cell receptor repertoire signature from the human peripheral blood.

Science advances·2026
Same author

Should Prediabetes Be Classified as a Treatable Disease?

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 6, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Autoimmune markers in diabetes.

William E Winter1, Desmond A Schatz

  • 1Department of Pathology, University of Florida, Gainesville, FL 32610-0275, USA. winter@pathology.ufl.edu

Clinical Chemistry
|December 4, 2010
PubMed
Summary
This summary is machine-generated.

Islet autoantibodies confirm autoimmune Type 1 diabetes (T1DM) in diagnosed individuals. In those without diabetes, these autoantibodies strongly predict future T1DM development, aiding early detection.

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

Related Experiment Videos

Last Updated: Jun 6, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

Area of Science:

  • Immunology
  • Endocrinology
  • Autoimmunity

Background:

  • Type 1 diabetes (T1DM) arises from autoimmune destruction of pancreatic beta cells.
  • Islet autoantibodies are key biomarkers for identifying and confirming beta-cell autoimmunity.

Purpose of the Study:

  • To define islet autoantibodies.
  • To describe their generation and clinical/research applications.
  • To discuss their appearance before and at T1DM onset.

Main Methods:

  • Review of existing literature on islet autoantibodies.
  • Analysis of their role in Type 1 diabetes pathogenesis.
  • Examination of their predictive value in at-risk individuals.

Main Results:

  • Islet autoantibodies confirm autoimmune etiology in diabetes.
  • Their presence in non-diabetic individuals predicts future T1DM.
  • Understanding their biology aids in T1DM prevention research.

Conclusions:

  • Islet autoantibodies are definitive markers of autoimmune diabetes.
  • They serve as crucial predictive tools for Type 1 diabetes development in at-risk populations.